The latter described the progress made by the Collaboration for Alzheimer’s Prevention (CAP), an umbrella group including two studies funded, in part, by GHR—the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) Study and the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU).
At the conference, director of DIAN-TU Randall Bateman spoke on the progress of the CAP partnership. Despite differences in populations, the four studies have found common ground on a clear set of cognitive domains to test and compare results. All CAP trials now also plan to use tau imaging, thanks to a partnership between the NIH and 10 industry partners.
CAP’s updates, while notable, are only a portion of the rapidly changing landscape of Alzheimer’s research. Other notable progressions presented at CTAD, such as the new compounds being developed and the creation of the Alzheimer’s Prevention Registry to accelerate enrollment in trials, will intersect with GHR’s Health Initiative’s involvement as organizations and researchers work together to find effective treatment.